Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Non-Current Deffered Revenue (2024 - 2025)

Historic Non-Current Deffered Revenue for Collegium Pharmaceutical (COLL) over the last 2 years, with Q3 2025 value amounting to $9.3 million.

  • Collegium Pharmaceutical's Non-Current Deffered Revenue fell 722.0% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year decrease of 722.0%. This contributed to the annual value of $10.0 million for FY2024, which is N/A changed from last year.
  • Per Collegium Pharmaceutical's latest filing, its Non-Current Deffered Revenue stood at $9.3 million for Q3 2025, which was down 722.0% from $10.0 million recorded in Q2 2025.
  • Collegium Pharmaceutical's Non-Current Deffered Revenue's 5-year high stood at $10.0 million during Q3 2024, with a 5-year trough of $9.3 million in Q3 2025.